Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Recommended Molecular Testing in Acute Myeloid Leukemia

January 19th 2018

The Microenvironment and Epigenetics in AML

January 19th 2018

Acute Myeloid Leukemia: Understanding Biologic Drivers

January 19th 2018

Expert Highlights Advances in Cutaneous T-Cell Lymphoma

January 19th 2018

Wei Z. Ai, MD, discusses the impact of brentuximab vedotin, as well as the potential with mogamulizumab in cutaneous T-cell lymphoma.

Dr. Mannis Talks About Emerging Treatments for Acute Myeloid Leukemia

January 19th 2018

Gabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses new methods of treatment for acute myeloid leukemia.

Addressing Unmet Needs in CMV Infection

January 18th 2018

Considerations for Utilizing Letermovir in Practice

January 18th 2018

Research Findings in CMV Infection

January 18th 2018

Monitoring Patients and Initiating Treatment in CMV

January 18th 2018

Current Strategies for Managing CMV Infection

January 18th 2018

Risk Stratification in CMV Infection

January 18th 2018

Prevalence and Risk Factors for CMV Infection

January 18th 2018

Ongoing Research for CMV Management in HSCT Patients

January 18th 2018

Practical Considerations for Administering Letermovir

January 18th 2018

Letermovir as CMV Prophylaxis in HSCT Patients

January 18th 2018

Preemptive Therapy For CMV Reactivation in HSCT

January 18th 2018

Burden of CMV Infection in HSCT Patients

January 18th 2018

FDA Grants Tisagenlecleucel Priority Review for DLBCL

January 17th 2018

The FDA has granted a priority review to the CAR T-cell therapy tisagenlecleucel for adult patients with relapsed/refractory DLBCL who are ineligible for or relapse after autologous stem cell transplant.

FDA Approves Arsenic Trioxide for Promyelocytic Leukemia

January 16th 2018

The FDA has approved arsenic trioxide (Trisenox) in combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or PML-RARA gene expression.

Considerations for Treating ITP in the Future

January 15th 2018